Hemoglobinopathies Market By Type (Thalassemia, Sickle Cell Disease, Others), By Therapy (Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea, Others), By Distribution Channel (Hospital Pharmacy, Online Providers, Drug Stores and Retail Pharmacy):
Description
Hemoglobinopathies Market By Type (Thalassemia, Sickle Cell Disease, Others), By Therapy (Monoclonal Antibody Medication, ACE inhibitors, Hydroxyurea, Others), By Distribution Channel (Hospital Pharmacy, Online Providers, Drug Stores and Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
Hemoglobinopathy is a collective term used for the blood disorder that primarily affects the red blood cells (RBCs). The abnormal production or structural change in the hemoglobin molecule causes hemoglobinopathies. Majorly, hemoglobinopathies are divided into two groups, namely abnormal structural hemoglobin variant and thalassemia. The abnormal structural hemoglobin variants are caused by mutations in the hemoglobin gene structure and thalassemia is occurred by abnormal or underproduction of hemoglobin molecules. Many hemoglobinopathies currently have some approved drugs in the market and some drugs are in development stages.
The increasing prevalence of sickle cell disease (SCD) and thalassemia is expected to drive the market growth. The key driver for the growth of the global hemoglobinopathies market is increasing prevalence of hemoglobinopathies in under-developed and developing countries. In addition, the lack of awareness and low diagnosis rate are some major factors increasing the prevalence of the hemoglobinopathies. Moreover, the lack of treatment alternatives, unavailability of treatments and low diagnosis rate are the factors restraining the growth of the global hemoglobinopathies market during the forecast period. The hemoglobinopathies market is projected to grow with the arrival of treatments for beta thalassemia and sickle cell diseases. Treatments based on transfer of genetically corrected stem cells, in which the lentiviral vectors transfer beta globin chain, and the transcription is regulated by the beta globin locus. For instance, there are various factors limiting growth of the market, such as insufficient stem-cell quantity and quality, gene expression complexity, and high cost of the treatment.
The hemoglobinopathies market is segmented on the basis of disease type, type of therapy, distribution channel, and region. By disease type, the market is segmented into thalassemia, sickle cell disease, and others. The other segment is further classified into hemoglobin (Hb) variants, beta thalassemia, alpha thalassemia, and porphyria. On the basis of type of therapy, the market is segmented into monoclonal antibody medication, angiotensin-converting enzyme (ACE) inhibitors, stem cell transplantation, hydroxyurea, and others. The other segment is further classified into gene therapy, iron chelation therapy, blood transfusion, and bone marrow transplant. By distribution channel, the market is segmented into hospital pharmacy, online providers, and drug stores and retail pharmacy.
Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Major key players that operate in the global hemoglobinopathies market are Abbott Laboratories, Alnylam Pharmaceuticals, Biogen Idec, Bluebird, Inc, Bristol Myers Squibb Company, Canthera Discovery Ltd., Danaher, Emmacus Life Science Inc, F. Hoffman-La Roche Ag, Gamida Cell Ltd, Global blood therapeutics, Merck & Co., Novartis AG, Pfizer, Inc, Prolong Pharmaceuticals, LLC, Sangamo Therapeutics, and Sanofi.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hemoglobinopathies market analysis from 2021 to 2031 to identify the prevailing hemoglobinopathies market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hemoglobinopathies market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hemoglobinopathies market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Thalassemia
Sickle Cell Disease
Others
By Therapy
Monoclonal Antibody Medication
ACE inhibitors
Hydroxyurea
Others
By Distribution Channel
Hospital Pharmacy
Online Providers
Drug Stores and Retail Pharmacy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Abbott Laboratories
Alnylam Pharmaceuticals, Inc.
Biogen idc
Bluebird, Inc.
Bristol Myers Squibb
Danaher Corporation
Emmaus Life Sciences, Inc.
Global Blood Therapeutics, Inc.
Merck & Co. Inc.
Novartis AG
Pfizer
Prolong Pharmaceuticals
Sangamo Therapeutics, Inc.
Sanofi
Cancer Therapeutics CRC Pty Ltd
Gamida-Cell Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Hemoglobinopathy is a collective term used for the blood disorder that primarily affects the red blood cells (RBCs). The abnormal production or structural change in the hemoglobin molecule causes hemoglobinopathies. Majorly, hemoglobinopathies are divided into two groups, namely abnormal structural hemoglobin variant and thalassemia. The abnormal structural hemoglobin variants are caused by mutations in the hemoglobin gene structure and thalassemia is occurred by abnormal or underproduction of hemoglobin molecules. Many hemoglobinopathies currently have some approved drugs in the market and some drugs are in development stages.
The increasing prevalence of sickle cell disease (SCD) and thalassemia is expected to drive the market growth. The key driver for the growth of the global hemoglobinopathies market is increasing prevalence of hemoglobinopathies in under-developed and developing countries. In addition, the lack of awareness and low diagnosis rate are some major factors increasing the prevalence of the hemoglobinopathies. Moreover, the lack of treatment alternatives, unavailability of treatments and low diagnosis rate are the factors restraining the growth of the global hemoglobinopathies market during the forecast period. The hemoglobinopathies market is projected to grow with the arrival of treatments for beta thalassemia and sickle cell diseases. Treatments based on transfer of genetically corrected stem cells, in which the lentiviral vectors transfer beta globin chain, and the transcription is regulated by the beta globin locus. For instance, there are various factors limiting growth of the market, such as insufficient stem-cell quantity and quality, gene expression complexity, and high cost of the treatment.
The hemoglobinopathies market is segmented on the basis of disease type, type of therapy, distribution channel, and region. By disease type, the market is segmented into thalassemia, sickle cell disease, and others. The other segment is further classified into hemoglobin (Hb) variants, beta thalassemia, alpha thalassemia, and porphyria. On the basis of type of therapy, the market is segmented into monoclonal antibody medication, angiotensin-converting enzyme (ACE) inhibitors, stem cell transplantation, hydroxyurea, and others. The other segment is further classified into gene therapy, iron chelation therapy, blood transfusion, and bone marrow transplant. By distribution channel, the market is segmented into hospital pharmacy, online providers, and drug stores and retail pharmacy.
Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Major key players that operate in the global hemoglobinopathies market are Abbott Laboratories, Alnylam Pharmaceuticals, Biogen Idec, Bluebird, Inc, Bristol Myers Squibb Company, Canthera Discovery Ltd., Danaher, Emmacus Life Science Inc, F. Hoffman-La Roche Ag, Gamida Cell Ltd, Global blood therapeutics, Merck & Co., Novartis AG, Pfizer, Inc, Prolong Pharmaceuticals, LLC, Sangamo Therapeutics, and Sanofi.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hemoglobinopathies market analysis from 2021 to 2031 to identify the prevailing hemoglobinopathies market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hemoglobinopathies market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hemoglobinopathies market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
Thalassemia
Sickle Cell Disease
Others
By Therapy
Monoclonal Antibody Medication
ACE inhibitors
Hydroxyurea
Others
By Distribution Channel
Hospital Pharmacy
Online Providers
Drug Stores and Retail Pharmacy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Abbott Laboratories
Alnylam Pharmaceuticals, Inc.
Biogen idc
Bluebird, Inc.
Bristol Myers Squibb
Danaher Corporation
Emmaus Life Sciences, Inc.
Global Blood Therapeutics, Inc.
Merck & Co. Inc.
Novartis AG
Pfizer
Prolong Pharmaceuticals
Sangamo Therapeutics, Inc.
Sanofi
Cancer Therapeutics CRC Pty Ltd
Gamida-Cell Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
315 Pages
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: HEMOGLOBINOPATHIES MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Thalassemia
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Sickle Cell Disease
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Others
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- CHAPTER 5: HEMOGLOBINOPATHIES MARKET, BY THERAPY
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Monoclonal Antibody Medication
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 ACE inhibitors
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Hydroxyurea
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Others
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- CHAPTER 6: HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital Pharmacy
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Online Providers
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Drug Stores and Retail Pharmacy
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: HEMOGLOBINOPATHIES MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Therapy
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Type
- 7.2.5.1.2 Market size and forecast, by Therapy
- 7.2.5.1.3 Market size and forecast, by Distribution Channel
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Type
- 7.2.5.2.2 Market size and forecast, by Therapy
- 7.2.5.2.3 Market size and forecast, by Distribution Channel
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Type
- 7.2.5.3.2 Market size and forecast, by Therapy
- 7.2.5.3.3 Market size and forecast, by Distribution Channel
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Therapy
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Type
- 7.3.5.1.2 Market size and forecast, by Therapy
- 7.3.5.1.3 Market size and forecast, by Distribution Channel
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Type
- 7.3.5.2.2 Market size and forecast, by Therapy
- 7.3.5.2.3 Market size and forecast, by Distribution Channel
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Type
- 7.3.5.3.2 Market size and forecast, by Therapy
- 7.3.5.3.3 Market size and forecast, by Distribution Channel
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Type
- 7.3.5.4.2 Market size and forecast, by Therapy
- 7.3.5.4.3 Market size and forecast, by Distribution Channel
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Type
- 7.3.5.5.2 Market size and forecast, by Therapy
- 7.3.5.5.3 Market size and forecast, by Distribution Channel
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Type
- 7.3.5.6.2 Market size and forecast, by Therapy
- 7.3.5.6.3 Market size and forecast, by Distribution Channel
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Therapy
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Type
- 7.4.5.1.2 Market size and forecast, by Therapy
- 7.4.5.1.3 Market size and forecast, by Distribution Channel
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Type
- 7.4.5.2.2 Market size and forecast, by Therapy
- 7.4.5.2.3 Market size and forecast, by Distribution Channel
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Type
- 7.4.5.3.2 Market size and forecast, by Therapy
- 7.4.5.3.3 Market size and forecast, by Distribution Channel
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Type
- 7.4.5.4.2 Market size and forecast, by Therapy
- 7.4.5.4.3 Market size and forecast, by Distribution Channel
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Type
- 7.4.5.5.2 Market size and forecast, by Therapy
- 7.4.5.5.3 Market size and forecast, by Distribution Channel
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Type
- 7.4.5.6.2 Market size and forecast, by Therapy
- 7.4.5.6.3 Market size and forecast, by Distribution Channel
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Therapy
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Type
- 7.5.5.1.2 Market size and forecast, by Therapy
- 7.5.5.1.3 Market size and forecast, by Distribution Channel
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Type
- 7.5.5.2.2 Market size and forecast, by Therapy
- 7.5.5.2.3 Market size and forecast, by Distribution Channel
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Type
- 7.5.5.3.2 Market size and forecast, by Therapy
- 7.5.5.3.3 Market size and forecast, by Distribution Channel
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Type
- 7.5.5.4.2 Market size and forecast, by Therapy
- 7.5.5.4.3 Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Abbott Laboratories
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Alnylam Pharmaceuticals, Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Biogen idc
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Bluebird, Inc.
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Bristol Myers Squibb
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Danaher Corporation
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Emmaus Life Sciences, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Global Blood Therapeutics, Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Merck & Co. Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Novartis AG
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- 9.11 Pfizer
- 9.11.1 Company overview
- 9.11.2 Company snapshot
- 9.11.3 Operating business segments
- 9.11.4 Product portfolio
- 9.11.5 Business performance
- 9.11.6 Key strategic moves and developments
- 9.12 Prolong Pharmaceuticals
- 9.12.1 Company overview
- 9.12.2 Company snapshot
- 9.12.3 Operating business segments
- 9.12.4 Product portfolio
- 9.12.5 Business performance
- 9.12.6 Key strategic moves and developments
- 9.13 Sangamo Therapeutics, Inc.
- 9.13.1 Company overview
- 9.13.2 Company snapshot
- 9.13.3 Operating business segments
- 9.13.4 Product portfolio
- 9.13.5 Business performance
- 9.13.6 Key strategic moves and developments
- 9.14 Sanofi
- 9.14.1 Company overview
- 9.14.2 Company snapshot
- 9.14.3 Operating business segments
- 9.14.4 Product portfolio
- 9.14.5 Business performance
- 9.14.6 Key strategic moves and developments
- 9.15 Cancer Therapeutics CRC Pty Ltd
- 9.15.1 Company overview
- 9.15.2 Company snapshot
- 9.15.3 Operating business segments
- 9.15.4 Product portfolio
- 9.15.5 Business performance
- 9.15.6 Key strategic moves and developments
- 9.16 Gamida-Cell Ltd.
- 9.16.1 Company overview
- 9.16.2 Company snapshot
- 9.16.3 Operating business segments
- 9.16.4 Product portfolio
- 9.16.5 Business performance
- 9.16.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 2. HEMOGLOBINOPATHIES MARKET SIZE, FOR THALASSEMIA, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. HEMOGLOBINOPATHIES MARKET FOR THALASSEMIA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. HEMOGLOBINOPATHIES MARKET SIZE, FOR SICKLE CELL DISEASE, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. HEMOGLOBINOPATHIES MARKET FOR SICKLE CELL DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. HEMOGLOBINOPATHIES MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. HEMOGLOBINOPATHIES MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. GLOBAL HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 9. HEMOGLOBINOPATHIES MARKET SIZE, FOR MONOCLONAL ANTIBODY MEDICATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. HEMOGLOBINOPATHIES MARKET FOR MONOCLONAL ANTIBODY MEDICATION, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 11. HEMOGLOBINOPATHIES MARKET SIZE, FOR ACE INHIBITORS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. HEMOGLOBINOPATHIES MARKET FOR ACE INHIBITORS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. HEMOGLOBINOPATHIES MARKET SIZE, FOR HYDROXYUREA, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. HEMOGLOBINOPATHIES MARKET FOR HYDROXYUREA, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. HEMOGLOBINOPATHIES MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. HEMOGLOBINOPATHIES MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. GLOBAL HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 18. HEMOGLOBINOPATHIES MARKET SIZE, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 19. HEMOGLOBINOPATHIES MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 20. HEMOGLOBINOPATHIES MARKET SIZE, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. HEMOGLOBINOPATHIES MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 22. HEMOGLOBINOPATHIES MARKET SIZE, FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. HEMOGLOBINOPATHIES MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 24. HEMOGLOBINOPATHIES MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. NORTH AMERICA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 26. NORTH AMERICA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 27. NORTH AMERICA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 28. NORTH AMERICA HEMOGLOBINOPATHIES MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 29. U.S. HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 30. U.S. HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 31. U.S. HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 32. CANADA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 33. CANADA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 34. CANADA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 35. MEXICO HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 36. MEXICO HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 37. MEXICO HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 38. EUROPE HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 39. EUROPE HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 40. EUROPE HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 41. EUROPE HEMOGLOBINOPATHIES MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 42. GERMANY HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 43. GERMANY HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 44. GERMANY HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 45. FRANCE HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 46. FRANCE HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 47. FRANCE HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 48. UK HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 49. UK HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 50. UK HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 51. ITALY HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 52. ITALY HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 53. ITALY HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 54. SPAIN HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 55. SPAIN HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 56. SPAIN HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 57. REST OF EUROPE HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 58. REST OF EUROPE HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 59. REST OF EUROPE HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 60. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 61. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 62. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 63. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 64. JAPAN HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 65. JAPAN HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 66. JAPAN HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 67. CHINA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 68. CHINA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 69. CHINA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 70. AUSTRALIA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 71. AUSTRALIA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 72. AUSTRALIA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 73. INDIA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 74. INDIA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 75. INDIA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 76. SOUTH KOREA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 77. SOUTH KOREA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 78. SOUTH KOREA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 79. REST OF ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 80. REST OF ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 81. REST OF ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 82. LAMEA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 83. LAMEA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 84. LAMEA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 85. LAMEA HEMOGLOBINOPATHIES MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 86. BRAZIL HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 87. BRAZIL HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 88. BRAZIL HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 89. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 90. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 91. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 92. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 93. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 94. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 95. REST OF LAMEA HEMOGLOBINOPATHIES MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 96. REST OF LAMEA HEMOGLOBINOPATHIES MARKET, BY THERAPY, 2021-2031 ($MILLION)
- TABLE 97. REST OF LAMEA HEMOGLOBINOPATHIES MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
- TABLE 98.ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 99.ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 100.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 101.ABBOTT LABORATORIES: NET SALES,
- TABLE 102.ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 103.ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
- TABLE 104.ALNYLAM PHARMACEUTICALS, INC.: OPERATING SEGMENTS
- TABLE 105.ALNYLAM PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
- TABLE 106.ALNYLAM PHARMACEUTICALS, INC.: NET SALES,
- TABLE 107.ALNYLAM PHARMACEUTICALS, INC.: KEY STRATERGIES
- TABLE 108.BIOGEN IDC: COMPANY SNAPSHOT
- TABLE 109.BIOGEN IDC: OPERATING SEGMENTS
- TABLE 110.BIOGEN IDC: PRODUCT PORTFOLIO
- TABLE 111.BIOGEN IDC: NET SALES,
- TABLE 112.BIOGEN IDC: KEY STRATERGIES
- TABLE 113.BLUEBIRD, INC.: COMPANY SNAPSHOT
- TABLE 114.BLUEBIRD, INC.: OPERATING SEGMENTS
- TABLE 115.BLUEBIRD, INC.: PRODUCT PORTFOLIO
- TABLE 116.BLUEBIRD, INC.: NET SALES,
- TABLE 117.BLUEBIRD, INC.: KEY STRATERGIES
- TABLE 118.BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT
- TABLE 119.BRISTOL MYERS SQUIBB: OPERATING SEGMENTS
- TABLE 120.BRISTOL MYERS SQUIBB: PRODUCT PORTFOLIO
- TABLE 121.BRISTOL MYERS SQUIBB: NET SALES,
- TABLE 122.BRISTOL MYERS SQUIBB: KEY STRATERGIES
- TABLE 123.DANAHER CORPORATION: COMPANY SNAPSHOT
- TABLE 124.DANAHER CORPORATION: OPERATING SEGMENTS
- TABLE 125.DANAHER CORPORATION: PRODUCT PORTFOLIO
- TABLE 126.DANAHER CORPORATION: NET SALES,
- TABLE 127.DANAHER CORPORATION: KEY STRATERGIES
- TABLE 128.EMMAUS LIFE SCIENCES, INC.: COMPANY SNAPSHOT
- TABLE 129.EMMAUS LIFE SCIENCES, INC.: OPERATING SEGMENTS
- TABLE 130.EMMAUS LIFE SCIENCES, INC.: PRODUCT PORTFOLIO
- TABLE 131.EMMAUS LIFE SCIENCES, INC.: NET SALES,
- TABLE 132.EMMAUS LIFE SCIENCES, INC.: KEY STRATERGIES
- TABLE 133.GLOBAL BLOOD THERAPEUTICS, INC.: COMPANY SNAPSHOT
- TABLE 134.GLOBAL BLOOD THERAPEUTICS, INC.: OPERATING SEGMENTS
- TABLE 135.GLOBAL BLOOD THERAPEUTICS, INC.: PRODUCT PORTFOLIO
- TABLE 136.GLOBAL BLOOD THERAPEUTICS, INC.: NET SALES,
- TABLE 137.GLOBAL BLOOD THERAPEUTICS, INC.: KEY STRATERGIES
- TABLE 138.MERCK & CO. INC.: COMPANY SNAPSHOT
- TABLE 139.MERCK & CO. INC.: OPERATING SEGMENTS
- TABLE 140.MERCK & CO. INC.: PRODUCT PORTFOLIO
- TABLE 141.MERCK & CO. INC.: NET SALES,
- TABLE 142.MERCK & CO. INC.: KEY STRATERGIES
- TABLE 143.NOVARTIS AG: COMPANY SNAPSHOT
- TABLE 144.NOVARTIS AG: OPERATING SEGMENTS
- TABLE 145.NOVARTIS AG: PRODUCT PORTFOLIO
- TABLE 146.NOVARTIS AG: NET SALES,
- TABLE 147.NOVARTIS AG: KEY STRATERGIES
- TABLE 148.PFIZER: COMPANY SNAPSHOT
- TABLE 149.PFIZER: OPERATING SEGMENTS
- TABLE 150.PFIZER: PRODUCT PORTFOLIO
- TABLE 151.PFIZER: NET SALES,
- TABLE 152.PFIZER: KEY STRATERGIES
- TABLE 153.PROLONG PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 154.PROLONG PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 155.PROLONG PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 156.PROLONG PHARMACEUTICALS: NET SALES,
- TABLE 157.PROLONG PHARMACEUTICALS: KEY STRATERGIES
- TABLE 158.SANGAMO THERAPEUTICS, INC.: COMPANY SNAPSHOT
- TABLE 159.SANGAMO THERAPEUTICS, INC.: OPERATING SEGMENTS
- TABLE 160.SANGAMO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
- TABLE 161.SANGAMO THERAPEUTICS, INC.: NET SALES,
- TABLE 162.SANGAMO THERAPEUTICS, INC.: KEY STRATERGIES
- TABLE 163.SANOFI: COMPANY SNAPSHOT
- TABLE 164.SANOFI: OPERATING SEGMENTS
- TABLE 165.SANOFI: PRODUCT PORTFOLIO
- TABLE 166.SANOFI: NET SALES,
- TABLE 167.SANOFI: KEY STRATERGIES
- TABLE 168.CANCER THERAPEUTICS CRC PTY LTD: COMPANY SNAPSHOT
- TABLE 169.CANCER THERAPEUTICS CRC PTY LTD: OPERATING SEGMENTS
- TABLE 170.CANCER THERAPEUTICS CRC PTY LTD: PRODUCT PORTFOLIO
- TABLE 171.CANCER THERAPEUTICS CRC PTY LTD: NET SALES,
- TABLE 172.CANCER THERAPEUTICS CRC PTY LTD: KEY STRATERGIES
- TABLE 173.GAMIDA-CELL LTD.: COMPANY SNAPSHOT
- TABLE 174.GAMIDA-CELL LTD.: OPERATING SEGMENTS
- TABLE 175.GAMIDA-CELL LTD.: PRODUCT PORTFOLIO
- TABLE 176.GAMIDA-CELL LTD.: NET SALES,
- TABLE 177.GAMIDA-CELL LTD.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.HEMOGLOBINOPATHIES MARKET SEGMENTATION
- FIGURE 2.HEMOGLOBINOPATHIES MARKET,2021-2031
- FIGURE 3.HEMOGLOBINOPATHIES MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.HEMOGLOBINOPATHIES MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.HEMOGLOBINOPATHIES MARKET,BY TYPE,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF THALASSEMIA HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SICKLE CELL DISEASE HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 16.HEMOGLOBINOPATHIES MARKET,BY THERAPY,2021(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF MONOCLONAL ANTIBODY MEDICATION HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ACE INHIBITORS HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HYDROXYUREA HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 21.HEMOGLOBINOPATHIES MARKET,BY DISTRIBUTION CHANNEL,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACY HEMOGLOBINOPATHIES MARKET,2021-2031(%)
- FIGURE 25.HEMOGLOBINOPATHIES MARKET BY REGION,2021
- FIGURE 26.U.S. HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 27.CANADA HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 28.MEXICO HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 29.GERMANY HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 30.FRANCE HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 31.UK HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 32.ITALY HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 33.SPAIN HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 34.REST OF EUROPE HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 35.JAPAN HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 36.CHINA HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 37.AUSTRALIA HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 38.INDIA HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 39.SOUTH KOREA HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 40.REST OF ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 41.BRAZIL HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 42.SAUDI ARABIA HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 43.SOUTH AFRICA HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 44.REST OF LAMEA HEMOGLOBINOPATHIES MARKET,2021-2031($MILLION)
- FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 49.COMPETITIVE DASHBOARD
- FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 51.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
- FIGURE 52.ALNYLAM PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
- FIGURE 53.BIOGEN IDC.: NET SALES ,($MILLION)
- FIGURE 54.BLUEBIRD, INC..: NET SALES ,($MILLION)
- FIGURE 55.BRISTOL MYERS SQUIBB.: NET SALES ,($MILLION)
- FIGURE 56.DANAHER CORPORATION.: NET SALES ,($MILLION)
- FIGURE 57.EMMAUS LIFE SCIENCES, INC..: NET SALES ,($MILLION)
- FIGURE 58.GLOBAL BLOOD THERAPEUTICS, INC..: NET SALES ,($MILLION)
- FIGURE 59.MERCK & CO. INC..: NET SALES ,($MILLION)
- FIGURE 60.NOVARTIS AG.: NET SALES ,($MILLION)
- FIGURE 61.PFIZER.: NET SALES ,($MILLION)
- FIGURE 62.PROLONG PHARMACEUTICALS.: NET SALES ,($MILLION)
- FIGURE 63.SANGAMO THERAPEUTICS, INC..: NET SALES ,($MILLION)
- FIGURE 64.SANOFI.: NET SALES ,($MILLION)
- FIGURE 65.CANCER THERAPEUTICS CRC PTY LTD.: NET SALES ,($MILLION)
- FIGURE 66.GAMIDA-CELL LTD..: NET SALES ,($MILLION)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
